UPCOMING: WuXi Representatives Visit Israel for EFMC-ASMC’15
Members of WuXi’s small molecule drug discovery platform (International Discovery Service Unit – IDSU) will be attending the EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry from November 15-18 to meet with Israeli clients and colleagues. WuXi brings world class capability and capacity through its open access platform so that anyone and any company can discover and develop healthcare products to benefit patients.
“Our team looks forward to fostering the small molecule innovation of Israeli entrepreneurs and to helping advance the world class science found in Israel” says Richard Soll, Senior VP, IDSU.
“I look forward to catching up with current and prospective clients face-to-face, and continuing to find ways to support and build our partnerships in this exciting discovery hub” says David Madge, IDSU’s Program Director.
Please contact Dana Yarden, Executive Director of Business Development, Israel for further details on WuXi’s services and IDSU’s trip to Israel.
Prospects for U.S. and Israel Cell and Gene Therapy: An Interview with Alan Moore, Vice President of Strategic Accounts and Cell Manufacturing
As the new head of the International Discovery Services Unit (IDSU), I am proud to introduce our quarterly newsletter, bringing you the latest in medicinal chemistry and small molecule news, research, and events.
For over a decade, WuXi AppTec has built an open access capability and technology platform with a broad and integrated portfolio of services throughout the drug R&D process to enable more efficient and cost-effective research that delivers innovative medicines and treatments to patients.
IDSU is a global synthetic and medicinal chemistry solutions platform that fosters strong collaboration between pharmaceutical and biotech companies, research institutes, and innovation hubs to provide comprehensive solutions to drug discovery challenges in our industry. Our global team leverages their peer-recognized chemistry and medchem expertise and WuXis best-in-class fully integrated drug discovery and development platform to seamlessly progress programs from target through to preclinical candidate selection and beyond. Over the last several years, IDSUs integrated discovery platform delivered more than 20 PCCs (Preclinical Candidates). In 2014, IDSUs medicinal chemistry support delivered over 70,000 compounds to 100+ clients worldwide.
We hope to continue this growth and further engage with the clients and life science communities we serve.
In the spirit of growth and collaboration, we hope you find value in this community newsletter.